Alcohol dependence and harmful use of alcohol - Diagnosis and treatment options;Abhängigkeit und schädlicher Gebrauch von Alkohol: Diagnostik und Behandlungsoptionen

Deutsches Arzteblatt International

Volumn 113, Issue 17, 2016, Pages 301-310

  Batra, Anil ^a   Müller, Christian A ^c   Mann, Karl ^b   Heinz, Andreas ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL;

ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; ADOLESCENT; ADULT; AGED; EVIDENCE BASED MEDICINE; FEMALE; GERMANY; HUMAN; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PREVALENCE; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALCOHOLISM; EVIDENCE-BASED MEDICINE; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84966430806     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2016.0301     Document Type: Article

References (39)

1. Mann K, Hoch E, Batra A: S3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener Störungen. Heidelberg: Springer 2015.
2. Rocco A, Compare D, Angrisani D, Sanduzzi Zamparelli M, Nardone G: Alcoholic disease: liver and beyond. World J Gastroenterol 2014, 20: 14652-9.
3. Mukamal KJ, Jadhav PP, D'Agostino RB, et al.: Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort. Circulation 2001, 104: 1367-73.
4. Knott CS, Coombs N, Stamatakis E, Biddulph JP: All cause mortality and the case for age specific alcohol consumption guidelines: pooled analyses of up to 10 population based cohorts. BMJ 2015; 350: h384.
5. Landgraf MN, Nothaber M, Kopp IB, Heinen F: Clinical practice guide - line: The diagnosis of fetal alcohol syndrome. Dtsch Arztebl Int 2013; 110: 703-10.
6. Statistisches Bundesamt: www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Gesundheit/Krankenhaeuser/Tabellen/DiagnosenInsgesamt.html;jsessionid=BC1BFC5DDBFD748FC963F019695C9656.cae3 (last accessed on 13 November 2015).
7. Nath B, Li Y, Carroll JE, Szabo G, Tseng JF, Shah SA: Alcohol exposure as a risk factor for adverse outcomes in elective surgery. J Gastrointest Surg 2010; 14: 1732-41.
8. Rüther T, Bobes J, De Hert M, et al.: EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. Eur Psychiatry 2014; 29: 65-82.
9. Di Chiara G, Imperato A: Drugs abused by humans preferentially in - crease synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA. 1988; 85: 5274-8.
10. Duncan J, Johnson S, Ou XM: Monoamine oxidases in major depressive disorder and alcoholism. Drug Discov Ther 2012; 6: 112-22.
11. Ho PS, Shih MC, Ma KH, et al.: Availability of the serotonin transporter in patients with alcohol dependence. World J Biol Psychiatry 2011; 12: 134-42.
12. Heinz AJ, Beck A, Meyer-Lindenberg A, Sterzer P, Heinz A: Cognitive and neurobiological mechanisms of alcohol-related aggression. Nature Reviews Neuroscience 2011; 12: 400-13.
13. Hannuksela ML, Liisanantti MK, Nissinen AET, Savolainen MJT: Bio chem - ical markers of alcoholism. Clin Chem Lab Med 2007; 45: 953-61.
14. Aradottir S, Asanovska G, Gjerss S, Hansson P, Alling C: Phosphatidyl - ethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. Alcohol and alcoholism 2006; 41: 431-7.
15. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V.: Alkoholbezogene Störungen: Screening, Dia - gnose und Behandlung. AWMF S3 Leitlinie. www.awmf.org/uploads/tx-szleitlinien/076-001l-S3-Leitlinie-Alkohol-2015-04.html (last accessed on 13 November 2015).
16. Norcross JC, Wampold BE: Evidence-based therapy relationships: research conclusions and clinical practices. Psychotherapy (Chic) 2011; 48: 98-102.
17. Erwin WE, Williams DB, Speir WA: Delirium tremens. South Med J 1998; 91: 425-32.
18. Zilker T: Alkoholentzugssyndrom und Delirium tremens. MMW 1999; 141: 26-30.
19. Hillbom M, Pieninkeroinen I, Leone M: Seizures in alcohol-dependent patients: epidemiology, pathophysiology and management. CNS Drugs 2003; 17:1013-30.
20. Lutz U, Batra A: Diagnostik und Therapie des Alkoholentzugssyndroms: Fokus auf Delirium tremens und Entzugskrampfanfall. Psych Praxis 2010; 37: 271-8.
21. Boothby LA, Doering RL: Acamprosate for the treatment of alcohol dependence. Clin Ther 2005; 27: 695-14.
22. Walter M, Dürsteler KM, Petitjean SA, Wiesbeck GA, Euler S, Sollberger D: Psychosocial treatment of addictive disorders-an overview of psychotherapeutic options and their efficacy. Fortschr Neurol Psychiatr 2015; 83: 201-10.
23. Mann K, Lehert P, Morgan MY: The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004; 28: 51-63.
24. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M: Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010; (12): CD001867.
25. Jonas DE, Arnick HR, Feltner C, et al.: Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014; 311: 1889-900.
26. Mann K, Leménager T, Hoffmann S, et al.: Results of a double-blind placebo controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol 2013; 18: 937-46.
27. Krampe H, Ehrenreich H: Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Des 2010; 16: 2076-90.
28. Niederhofer H, Staffen W: Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents. Drug Alcohol Rev 2003; 22: 295-7.
29. Krampe H, Stawicki S, Wagner T: Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res 2006; 30: 86-95.
30. Müller CA, Geisel O, Pelz P: High-dose baclofen for the treatment of alcohol dependence (BACLAD study): A randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2015; 8: 1167-77.
31. Körkel J: Kontrolliertes Trinken bei Alkoholkonsumstörungen: Eine systematische Übersicht. Sucht 2015; 6: 147-74.
32. Feuerlein W, Küfner HA: prospective multicenter study of in-patient treatment for alcoholics: 18- and 48-month follow-up (Munich Evaluation for Alcoholism Treatment, MEAT). Eur Arch Psychiatry Neurol Sci 1989; 239: 144-57.
33. Mann K, Schäfer DR, Längle G, Ackermann K, Croissant B: The long-term course of alcoholism, 5, 10 and 16 years after treatment. Addiction 2005; 100: 797-805.
34. Gual A, Bravo F, Lligoña A, Colom J: Treatment for alcohol dependence in Catalonia: health outcomes and stability of drinking patterns over 20 years in 850 patients. Alcohol and alcoholism 2009; 44: 409-15.
35. Adamson SJ, Heather N, Morton V, Raistrick D: Initial preference for drinking goal in the treatment of alcohol problems: II. Treatment outcomes. Alcohol Alcohol 2010; 45: 136-42.
36. Collins SE, Malone DK, Clifasefi SL: Housing retention in single-site housing first for chronically homeless individuals with severe alcohol problems. Am J Public Health 2013; 103: 269-74.
37. Collins SE, Clifasefi SL, Dana EA, et al.: Where harm reduction meets housing first: exploring alcohol's role in a project-based housing first setting. Int J Drug Policy 2012; 23: 111-9.
38. Collins SE, Grazioli VS, Torres NI, et al.: Qualitatively and quantitatively evaluating harm-reduction goal setting among chronically homeless individuals with alcohol dependence. Addict Behav 2015; 45: 184-90.
39. van den Brink W, Sørensen P, Torup L, Mann K, Gual A: Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. J Psychopharmacol 2014; 28: 733-44. G-BA: https://www.g-ba.de/downloads/39-261-2179/2015-02-19-AM-RL-XII-Nalmefen-2014-09-01-D-127-BAnz.pdf (last accessed on 12 February 2016).